Seeking Alpha

Merrimack continues its slide; sets another new 52-week low

  • Shares in Merrimack Pharmaceuticals (MACK -4.2%) move lower again today to set a new 52-week low once again.
  • Initially, the stock spiked more than 26% higher in the pre-market, possibly helped by a positive Seeking Alpha blog.
  • The SA contributor notes that MM-121, a therapeutic antibody for treating tumors, is the key drug in its portfolio. The company expects three trials involving MM-121 to report in late 2013.
  • If positive, I this could lead to a substantial revaluing of the company, and potentially an acquisition by a larger drug company.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|